Investors

Adamas Pharmaceuticals, Inc. is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its development program for ADS-5102 which is in development for the treatment of walking impairment in patients with multiple sclerosis. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society.

News and Events


Upcoming Events

There are currently no events to display.

Presentations



Stock Information